S-1-Propenylcysteine promotes IL-10-induced M2c macrophage polarization through prolonged activation of IL-10R/STAT3 signaling

Satomi Miki1,2,*, Jun-ichiro Suzuki2, Miyuki Takashima2, Mari Ishida1, Hiroki Kokubo1 & Masao Yoshizumi1,2

Atherosclerosis is a chronic inflammatory disease that may lead to the development of serious cardiovascular diseases. Aged garlic extract (AGE) has been reported to ameliorate atherosclerosis, although its mode of action remains unclear. We found that AGE increased the mRNA or protein levels of arginase1 (Arg1), interleukin-10 (IL-10), CD206 and hypoxia-inducible factor 2α (HIF2α) and decreased that of CD68, HIF1α and inducible nitric oxide synthase in the aorta and spleen of apolipoprotein E knockout mice. We also found that S-1-propenylcysteine (S1PC), a characteristic sulfur compound in AGE, increased the level of IL-10-induced Arg1 mRNA and the extent of M2c-like macrophage polarization in vitro. In addition, S1PC increased the population of M2c-like macrophages, resulting in suppressed the population of M1-like macrophages and decreased lipopolysaccharide-induced production of pro-inflammatory cytokines. These effects were accompanied by prolonged phosphorylation of the IL-10 receptor α (IL-10Rα) and signal transducer and activator of transcription 3 (STAT3) that inhibited the interaction between IL-10Rα and Src homology-2-containing inositol 5’-phosphatase 1 (SHIP1). In addition, administration of S1PC elevated the M2c/M1 macrophage ratio in senescence-accelerated mice. These findings suggest that S1PC may help improve atherosclerosis due to its anti-inflammatory effect to promote IL-10-induced M2c macrophage polarization.

Atherosclerosis is a chronic inflammatory disease that may lead to the development of life-threatening illnesses such as coronary artery disease (CAD), peripheral artery disease (PAD), and cerebrovascular disease. In the early stages of atherosclerosis, oxidized low density lipoproteins (oxLDL) induce inflammation in arterial walls, causing augmented infiltration of monocytes into the sub-endothelial space and differentiation of monocytes into macrophages. Subsequently, the arterial macrophages are transformed into foam cells, a process that is accompanied by the upregulation of several genes, such as CD36 and CD68. The foam cells then secrete pro-inflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α), into the arterial intima, promoting the formation of atherosclerotic plaques. The resulting chronic inflammation promotes the release of damage-associated molecular patterns (DAMPs), such as nucleic acids and proteins from dead cells, as well as senescence-associated secretory phenotype (SASP) factors, such as inflammatory cytokines, growth factors, and proteases from senescent cells. These accelerate vascular aging by creating a positive feedback loop and eventually exacerbating plaque formation.

Macrophages can be polarized to two major phenotypes depending on the microenvironmental conditions: pro-inflammatory M1 and anti-inflammatory M2 macrophages. It has been reported that the development of atherosclerosis alters the ratio of polarized macrophages. M1 macrophages promote the formation of atherosclerotic plaques by sustaining inflammation, whereas M2 macrophages aid the regression of atherosclerotic plaques.

1Department of Cardiovascular Physiology and Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima-shi, Hiroshima 734-8551, Japan. 2Central Research Institute, Wakunaga Pharmaceutical Co., Ltd., 1624 Shimokotachi, Koda-cho, Akitakata-shi, Hiroshima 739-1195, Japan. *email: miki_s@wakunaga.co.jp; yoshizum-tky@umin.ac.jp
plaques by promoting tissue repair, anti-inflammatory cytokine release, and efferocytosis through phagocytosis
of apoptotic cells4,15–16. Specifically, M2c macrophages inhibit the accumulation of foam cells by inducing mer
zyme kinase (MerTK)-dependent efferocytosis16,19. The polarization of macrophages to pro-inflammatory
M1 macrophages expressing TNF-α, CD68, IL-18, hypoxia-inducible factor 1α (HIF1α), C–C motif chemokine
ligand 5 (CCL5), CD86, and nitric oxide (NO) is elicited by exposure to pro-inflammatory cytokines such as
interferon-γ (IFN-γ) and TNF-α11,12,20–24. On the other hand, anti-inflammatory cytokine IL-10 induces polariza-
tion to anti-inflammatory M2c macrophages that produce IL-10, transforming growth factor-β (TGF-β),
arginase-1 (Arg1), CD206, scavenger receptor AI (SR-AI), Suppressor of cytokine signaling 3 (SOCS3),
and Cd15011,12,22,24–27.

The IL-10 receptor (IL-10R) consists of a tetrameric complex with two ligand-binding subunits (IL-10Rα)
and two accessory signaling subunits (IL-10Rβ)28–31. The binding of IL-10 to the extracellular domain of IL-10Rα
results in the phosphorylation of janus kinase-1 (JAK1) and tyrosine kinase-2 (TYK2), which interact with
IL-10Ra and IL-10Rβ, respectively29–31. Activated JAK1 then phosphorylates tyrosine residues such as Tyr446
and Tyr496 in the intracellular domain of the IL-10Rα subunits, leading to interactions between transcription factor
signal transducer and activator of transcription 3 (STAT3) via the Src homology-2 (SH2) domain31–33. Addition-
ally, phosphorylation of STAT3 at Tyr705 by JAK1 causes STAT3 dimerization in the cytoplasm. The dimerized
STAT3 translocates to the nucleus and binds to the promoter region of IL-10-responsive genes, resulting in
augmented transcription of M2c macrophage-associated genes31,33,34.

Aged garlic extract (AGE) has been shown to demonstrate various pharmacological actions including
antihypertensive35–37, cardiovascular protective38,39, and immunomodulatory effects40,41. It is prepared by aging
raw garlic (Allium sativum L.) in a water–ethanol mixture for more than 10 months at room temperature42,43.
AGE contains several water-soluble sulfur compounds such as S-1-propenylcysteine (SIPC)44–46. Recently, SIPC
has been shown to inhibit IL-6 production through autophagy activation, improve peripheral blood circulation,
by increasing the NOx production, and maintain endothelial barrier function44–46. We have previously reported
that AGE inhibits lipid deposition in apolipoprotein E knockout (ApoE-KO) mice, an atherosclerosis model47,48.
However, the underlying molecular mechanism and active constituents by which AGE improves atherosclerosis
in vivo have not yet been identified.

Here, we aimed to explore the mechanism underlying the anti-atherosclerotic effect of AGE.

Results

AGE inhibited the formation of atherosclerotic plaques and the M1/M2-like macrophage ratio
in ApoE-KO mice. To confirm the anti-atherosclerotic effect of AGE, we evaluated lipid accumulation in the
vascular tissue of ApoE-KO mice fed a standard diet containing 3% AGE for 17 weeks. As shown in Fig. 1a, Supple-
mental Fig. S1a and b, and Table S1, AGE decreased the Oil Red O-positive areas in the aorta of the ApoE-KO
mice compared with those of the mice fed normal diets, without altering the systemic lipid profiles.

We then investigated whether AGE affected macrophage polarization. Immunohistological staining showed
that AGE reduced the number of macrophages expressing iNOS, an M1 macrophage marker, in the athero-
lesiotic lesions of the mice (Supplemental Fig. S1d). In addition, AGE significantly suppressed the levels of Cd68
and Hif1α mRNA, out of five M1 macrophage marker genes (Cd68, Tnfa, Il-18, Hif1α, and Ccl5), in the whole
aorta (Fig. 1b). Furthermore, AGE also reduced the protein level of inducible nitric oxide synthase (iNOS) in the
spleen of the mice (Fig. 1d). On the other hand, AGE increased the number of macrophages expressing Arg1,
an M2 macrophage marker, in the atherosclerotic lesions of the mice (Supplemental Fig. S1e). Moreover, out of five M2
macrophage marker genes (Arg1, Mrc1 coding CD206, Epsa1 coding HIF2α, Msr1 coding SR-AI, and
Slamf1 coding CD150), AGE significantly increased the levels of Arg1, Mrc1 and Epsa1 mRNA in the whole aorta
(Fig. 1c). It also elevated the levels of Arg1, Il-10, and Cd206 proteins in the spleen of the mice (Fig. 1d). These
results suggested the possibility that AGE retards the progression of atherosclerosis partly through altering
the M1/M2 macrophage ratio in several tissues.

S1PC expanded the population of IL-10-induced M2c-like macrophages. IL-10 induces the
expression of Arg1, resulting in the polarization of macrophages to M2c macrophages49,50. Since AGE increased
the expression of Arg1 and IL-10 in ApoE-KO mice, we evaluated the effect of AGE on IL-10-induced increase
in Arg1 mRNA level in macrophage colony-stimulating factor (M-CSF)-induced bone marrow-derived mac-
rophages (BMDMs). We found that AGE significantly enhanced the level of Arg1 mRNA in recombinant mouse
IL-10 (mIL-10)-treated BMDMs but not without mIL-10 (Supplemental Fig. S2a).

We then examined the effect of S1PC (Supplemental Fig. S2b) on the expression of four M2 macrophage
maker genes in mIL-10-treated BMDMs. As shown in Fig. 2a, Supplemental Fig. S2c and d, S1PC upregulated
the levels of Il-10, Arg1, Socs3, and Epsa1 mRNA in the mIL-10-treated BMDMs, whereas S1PC had no effect on
the expression of these mRNAs without mIL-10. Next, we assessed whether S1PC promoted the polarization of
macrophages to M2c-like macrophages and found that S1PC increased the population of M2c-like macrophages
(CD11b+, F4/80+, Cd86, Cd206, and Cd150+ cells) when treated with mIL-10 for 48 h, but not 24 h and without
mIL-10 (Fig. 2b and Supplemental Fig. S2e). These results suggest that S1PC is a major active constituent in AGE
that promotes M2c-like macrophage polarization.

Distinctly polarized macrophages respond differently to toll-like receptor (TLR) 4 agonist lipopolysaccharides
(LPS), such that M1 macrophages produce IL-12 and M2 macrophages produce IL-10. To evaluate the anti-
inflammatory ability of S1PC-induced M2c-like macrophages, we measured IL-10 production in M-CSF-induced
BMDMs stimulated by LPS after treatment with recombinant human IL-10 (hIL-10) and S1PC. As shown in
Fig. 2c, the BMDMs treated with S1PC and hIL-10 increased the LPS-induced IL-10 production compared with
the macrophages treated with hIL-10 alone whereas S1PC-treated BMDMs without hIL-10 did not enhance
Figure 1. Effect of AGE on lipid deposition and M1/M2-macrophage marker expression in vascular tissue and spleen of ApoE-KO mice. C57BL/6 J (Control) and ApoE-KO mice were fed a diet with or without 3% AGE for 17 weeks. (a) Oil Red O staining of a thoracic aorta. Bar graphs show the percentage of the Oil Red O-positive area in the aorta. (b, c) The relative mRNA levels of (b) M1 macrophage marker genes (Cd68, Tnfa, Il-1β, Hif1α, and Ccl5) and (c) M2 macrophage marker genes (Arg1, Mrc1, Epas1, Msr1, and Slamf1) in aorta. (d) The relative protein levels of iNOS, Arg1, IL-10, and CD206 in splenic lymphocytes. Data were quantified by analyzing each band intensity relative to a β-actin band after immunoblotting. The full-length blots are shown in Supplemental Figs. S8 and S9. Data are shown as mean + SEM (n = 5–8/group). Statistical differences were determined by Bonferroni's multiple comparison test (*p < 0.05 and **p < 0.01).
IL-10 production induced by LPS. These results suggest that S1PC-treated M2c-like macrophages demonstrated high IL-10-producing abilities.

Next, we investigated the effect of S1PC on changes in M1/M2 macrophage polarization by examining a population of granulocyte–macrophage colony-stimulating factor (GM-CSF)-induced BMDMs treated with S1PC in the absence or presence of mIL-10 (Fig. 3a, b). The BMDMs treated with mIL-10 exhibited significantly increased populations of M2c- and M2-like macrophages (CD11b+, F4/80+, CD86-, and CD206+ cells) and decreased population of M1-like macrophages (CD11b+, F4/80+, CD86+, and CD206- cells) (Fig. 3b). In addition, S1PC treatment expanded the population of M2c-like macrophages in the presence of mIL-10 compared with BMDMs treated with mIL-10 alone. On the other hand, S1PC had no effect on the populations of M1- and M2-like macrophages in the absence or presence of mIL-10 (Fig. 3a, b). As shown in Fig. 3c, mIL-10-treated BMDMs had a higher percentage of M2-like macrophages, especially M2c-like macrophages, than M1-like macrophages in the presence of LPS, whereas BMDMs without mIL-10 showed a similar ratio of M1- to M2-like macrophages. In addition, S1PC and mIL-10-treated macrophages also exhibited greater reductions in the production of IL-12p70 (Fig. 3d) and TNF-α (Fig. 3e) induced by LPS compared with the cells treated with LPS alone. These results suggest the possibility that S1PC promotes IL-10 production via increasing the population of M2c-like macrophages and reduces the population of M1-like macrophages.

**S1PC prolonged the activation and nuclear localization of STAT3 by inhibiting the interaction between IL-10Rα and SHIP1.** The IL-10/IL-10R signaling cascade is the main pathway that controls macrophage polarization to the M2c phenotype. To investigate the effect of S1PC on this signaling cascade, we measured the phosphorylation levels of JAK1, IL-10Rα, and STAT3 in M-CSF-induced BMDMs treated with
Figure 3. Effect of S1PC on IL-10-induced macrophage polarization in GM-CSF-induced BMDMs. (a) Assay scheme. (b) GM-CSF-induced BMDMs were treated with S1PC (300 µM) in the presence or absence of mIL-10 (30 ng/mL) for 48 h. The populations of M1-like macrophages (CD11b⁺, F4/80⁺, CD86⁺, and CD206⁻ cells), M2-like macrophages (CD11b⁺, F4/80⁺, CD86⁻, and CD206⁺ cells), and M2c-like macrophages were analyzed using flow cytometry. (c–e) GM-CSF-induced BMDMs were treated with S1PC (300 µM) in the presence or absence of mIL-10 (30 ng/mL) for 48 h. Then, they were washed with PBS and treated with LPS (100 ng/mL) for 16 h. (c) The populations of M1-like macrophages, M2-like macrophages, and M2c-like macrophages were analyzed using flow cytometry. The amounts of (d) IL-12p70 and (e) TNF-α secreted into the culture media were determined using ELISA. Data are shown as mean ± SD. Data are representative of three independent experiments. Statistical differences were determined using Bonferroni's multiple comparison test (*p < 0.05 and **p < 0.01).
or without mIL-10. S1PC had no effect on the phosphorylation of IL-10Ra, JAK1 and STAT3 without mIL-10 (Fig. 4a). As shown in Fig. 4b–d and Supplemental Fig. 5a, S1PC and AGE treatment prolonged the elevated levels of mIL-10-induced IL-10Ra and STAT3 phosphorylation for up to 360 min. The activation of IL-10Ra and STAT3 by S1PC were found to be dependent on IL-10 stimulation. In addition, STAT3 was localized to the nucleus at 30 min after mIL-10 treatment with or without S1PC. However, its nuclear localization continued up to 360 min only in S1PC treatment (Fig. 4f). On the other hand, S1PC did not affect mIL-10-induced JAK1 phosphorylation (Fig. 4b, e). In addition, S1PC did not alter the extent of phosphorylation of STAT3, STAT1, and STAT6 induced by IL-6, LPS with IFN-γ, and IL-4, respectively, in M-CSF-induced BMDMs, indicating that S1PC specifically affects IL-10-mediated IL-10R/STAT3 signaling (Supplemental Fig. S4b–d).

In the present study, S1PC prolonged the mIL-10-induced phosphorylation of IL-10Ra without affecting the phosphorylation of JAK1. Thus, we evaluated the effect of S1PC on the interaction between IL-10Ra and protein phosphatases through an immunoprecipitation assay. As shown in Fig. 4g, S1PC suppressed the interaction of IL-10Ra with SH2-containing inositol 5′-phosphatase 1 (SHIP1) in a concentration-dependent manner in J774A.1 cells in the presence of mIL-10 but not in the absence of mIL-10. On the other hand, S1PC could not suppress the interplay between IL-10Ra with protein tyrosine phosphatase 1B (PTP1B) or SH2-containing protein tyrosine phosphatase-1 (SHIP-1) (Fig. 4h, i). In addition, S1PC had no effect on the protein levels of these phosphatases (Supplemental Fig. S5). Moreover, we found that the phosphorylation of IL-10Ra induced by mIL-10 was sustained in SHIP1-knockdown cells compared with control cells (Supplemental Fig. S6). These results suggest that S1PC treatment prolonged the IL-10–induced phosphorylation of IL-10Ra and STAT3 by suppressing the interaction between IL-10Ra and SHIP1, resulting in prolonged nuclear localization of STAT3 (Fig. 4j).

**S1PC increased the population of M2c-like macrophages in the senescence-accelerated mice.** Aging is a risk factor for atherosclerosis, and in aging tissues, macrophages shift to the M1 phenotype due to increased production of pro-inflammatory cytokines. Thus, we examined whether S1PC shifted macrophage polarization in senescence-accelerated mouse prone M2-like macrophages was significantly increased in the SAMP8 mice compared with senescence accelerated-resistant 1 (SAMR1) mice, and the population of M2c-like macrophages was further increased in the group treated with S1PC (Fig. 5a). In the SAMP8 mice, S1PC increased the protein levels of Arg1 and IL-10 in the spleen (Fig. 5b) as well mRNA levels of Arg1 and Mrc1 in the aorta (Fig. 5c, d). On the other hand, M1-like macrophages were found to be increased in the SAMP8 mice compared with the SAMR1 mice. However, S1PC significantly decreased the numbers of M1-like macrophages in the SAMP8 mice (Fig. 5a). Furthermore, S1PC enhanced the phosphorylation of STAT3 in the spleen of the SAMP8 mice at 60 min after oral administration of S1PC (Supplemental Fig. S7). These results suggest that S1PC promotes M2c-like macrophage polarization in senescent mice, regardless of the presence of atherosclerosis.

**Discussion**

While AGE contains various bioactive constituents, it is unclear which constituents are involved in the increase of M2 macrophages. Since S1PC, one of active constituents in AGE, has been reported to demonstrate various pharmacological effects, such as improving barrier function, peripheral blood flow and immunoregulatory function, we hypothesized that it was of interest to examine whether S1PC increased M2-like macrophages induced by mIL-10. In the present study, we found that AGE and its constituent S1PC altered the balance between pro-inflammatory and anti-inflammatory macrophage populations by promoting M2-like macrophage polarization in the aorta of ApoE-KO and SAMP8 mice.

In the atherosclerotic plaques of LDL receptor-KO mice, M1 macrophages predominate and account for approximately 40%, while M2 macrophages account for about 20% of the total number of macrophages. M1 macrophages were found to accelerate the formation of atherosclerotic plaques, while M2 macrophages were found to contribute to the suppression of both inflammation and plaque formation in an atherosclerosis mouse
model\textsuperscript{54–56}. Thus, the balance between the M1 and M2 macrophages play an important role in the formation and regression of atherosclerotic plaques.

Previous reports have shown that the Arg1/iNOS ratio is a key determinant in M1/M2 macrophage polarization\textsuperscript{57,58}. Arg1 is an enzyme that catalyzes the conversion of L-arginine to ornithine and urea, competing with the M1 macrophage marker-enzyme iNOS which utilizes L-arginine\textsuperscript{57,58}. It has been shown that the levels of iNOS and IL-6 are high in Arg1-deficient macrophages and low in Arg1-overexpressed macrophages, leading to reduced numbers of M1 macrophages\textsuperscript{57,58}. The increase in M2 macrophages induced by AGE and S1PC may be attributable to the enhanced expression of Arg1 in the aorta, spleen, and BMDMs of mice.

Figure 5. Effect of S1PC on macrophage polarization in SAMP8 mice. SAMR1 and SAMP8 mice were orally administered water and S1PC (5 mg/kg/day) for 6 weeks. (a) The populations of polarized macrophages in the splenic lymphocytes obtained from the SAMR1 and SAMP8 mice were analyzed using flow cytometry. Bar graphs show the populations of M1-like macrophages, M2-like macrophages, and M2c-like macrophages. (b) The relative protein levels of Arg1 and IL-10 in the splenic lymphocytes obtained from the SAMR1 and SAMP8 mice were determined using immunoblotting. The full-length blots are shown in Supplemental Fig. S16. (c) The relative mRNA levels of Arg1 and (d) Mrc1 in the aortas were determined using qRT-PCR. Data are shown as mean + SEM (n = 4–8/group). Statistical differences were determined using Bonferroni's multiple comparison test (*p < 0.05 and **p < 0.01).
The transcription of the Arg1 gene is induced by direct binding of STAT3 to the promoter region59. Furthermore, the phosphorylation of STAT3 is a critical step in IL-6R and IL-10R signaling that determines the switching between pro- and anti-inflammatory gene expression induced by IL-6 or IL-1060. Therefore, the prolongation of STAT3 phosphorylation and nuclear localization by S1PC may enhance the level of Arg1 mRNA. On the other hand, the expression of Arg1 is also induced by the activation of STAT6 via IL-4 treatment, which then induces the formation of M2a macrophages. We found that S1PC had no effect on the IL-4-induced phosphorylation of STAT6, suggesting that it does not affect the expression of Arg1 and the polarization of macrophages to M2a macrophages. S1PC was observed to affect only M2c-like macrophages polarization but not M2a macrophages by promoting the IL-10Ra-STAT3 signaling pathway.

Since S1PC prolonged the mIL-10-induced phosphorylation of IL-10Ra and STAT3, we hypothesized that S1PC may regulate the dephosphorylation of IL-10Ra through protein phosphatases. Several SH2 domain-containing protein phosphatases, including SHP-1, PTP1B, and SHIP1, have been shown to negatively regulate the JAK/STAT signaling pathway61-64. Thus, we also hypothesized that the prolongation of IL-10Ra phosphorylation was due to the inhibition of protein phosphatases against IL-10Ra. We found that SHIP1 interacted with IL-10Ra, and its interaction was inhibited by S1PC. Since knockdown of SHIP1 extended IL-10Ra activation, S1PC may sustain the phosphorylated state of IL-10Ra by blocking the interaction with SHIP1 and IL-10Ra. On the other hand, it has been reported that SHIP1 is important for IL-10R signaling because it interacts with STAT3 and translocates STAT3 to the nucleus65. It is likely that S1PC does not inhibit the interaction between STAT3 and SHIP1 because it sustains the nuclear localization of STAT3.

While AGE and S1PC directly promoted the polarization of macrophages to M2c macrophages, they may also have influenced their polarization to M1 macrophages. M2 macrophages produce IL-10 and TGF-β, which exert anti-inflammatory and tissue repair actions66. While IL-10 promotes polarization of macrophages to M2c macrophages by inducing phosphorylation of STAT3, it also suppresses their polarization to M1 macrophages and the production of pro-inflammatory cytokines through inhibition of STAT1 and NF-κB67. Since AGE and S1PC were observed to increase the production of IL-10 in the spleen with increased expressions of M2 macrophage marker proteins, they likely increased IL-10 production in the aorta, as well as observed by the increases in M2 macrophages. Therefore, M1 macrophage polarization reduced by AGE and S1PC may also be due to the increased IL-10 production by the expanded numbers of M2 macrophages. However, S1PC notably did not affect the IL-6-induced phosphorylation of STAT3 and LPS plus IFN-γ-induced phosphorylation of STAT1, suggesting that S1PC does not directly inhibit M1 macrophage polarization through the signaling pathway.

Inflammaging refers to chronic low-grade inflammation that occurs with aging and is a risk factor for atherosclerosis. Inflammaging is promoted by persistent increases in CRP and pro-inflammatory cytokines such as IL-6 and TNF-α68–74. The augmented release of DAMPs from damaged tissues and dead cells triggers an increase in inflammation. Inflammaging is promoted by persistent increases in CRP and pro-inflammatory cytokines such as IL-6 that S1PC does not directly inhibit M1 macrophage polarization through the polarization signaling pathway.

Methods
Preparation of AGE and S1PC. AGE was manufactured as follows: raw garlic (Allium sativum L.) was sliced, immersed in aqueous ethanol (20–50%), and incubated for more than 10 months at room temperature. The specific procedure and specifications are in compliance with the US Pharmacopeia/Natural Formula (USP/NF) for garlic fluid extract monograph85. S1PC was synthesized as previously described44,86,87 and the purity was >99.8%.

Antibodies and reagents. The antibodies used in this study are summarized in Supplemental Table S2. Recombinant mouse M-CSF (#576404), IL-10 (#575806) and IL-6 (#575702) were obtained from Biolegend. Recombinant mouse GM-CSF (#ab198564) was purchased from Abcam. Recombinant human IL-10 (#200-10)
was obtained from PeproTech. Recombinant mouse IFN-γ (#21-8311) and IL-4 (#21-8041) were purchased from TONBO biosciences. Oil Red O (#00625) and LPS (#L2630) were obtained from Sigma-Aldrich.

**Animals.** Male C57BL/6 J mice and ApoE-KO mice (B6.129P2-Apoem1Unc/J, 5 weeks old) were purchased from Charles River Japan. Male SAMRI and SAMP8 mice (5 weeks old) were purchased from Japan SLC. The animals were individually housed under a 12 h light–dark cycle with controlled temperature (22 ± 1 °C) and humidity (50 ± 5%) and had free access to food and water. The experiments were performed in accordance with protocols approved by the Wakunaga Pharmaceutical Company Institutional Animal Care and Use Committee (Permission No. 252 and 290). The procedures performed in this investigation conform to the Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health. The study was performed in accordance with ARRIVE guidelines.

**Quantitation of atherosclerosis.** C57BL/6 J (6 weeks old, n=5/group) and ApoE-KO mice (6 weeks old, n=8/group) were fed standard diets with or without 3% AGE (CLEA Japan) for 17 weeks. Then, their plasma, hearts, aortas, and spleens were collected. Plasma levels of triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and non-esterified fatty acid (NEFA) were quantified using commercially available kits (#432-40201, #439-17501, #431-52501, and #279-75401, respectively; FUJIFILM Wako Pure Chemical). The aortas were stained with Oil Red O solution for 20 min then washed with isopropanol and ultrapure water. The stained areas were analyzed using BZ-9000 (KEYENCE) and quantified using ImageJ software version 1.48 (National Institutes of Health).

**Immunohistological staining.** The upper half of the hearts were embedded in paraffin, and the aortic roots were sectioned at thicknesses of 4 µm. The sections were then deparaffinized and incubated with proteinase K (#34060-96, KANTO KAGAKU) at 37 °C for 30 min for antigen activation. After washing with PBS, the sections were blocked with PBS containing 5% BSA for 1 h at room temperature (RT). They were then incubated with primary antibodies at 4 °C overnight and subsequently incubated with anti-rabbit Alexa Fluor 488 and anti-mouse Alexa Fluor 647 (Life Technologies). The sections were mounted with DAPI-containing mounting medium. The stained sections were analyzed under a fluorescence microscope (Axio Observer7) using ZEN 3.1 pro software (ZEISS).

**Evaluation of macrophage polarization and STAT3 phosphorylation in vivo.** For the evaluation of macrophage polarity changes, SAMRI and SAMP8 mice (8 weeks old) were divided into the 3 groups (n = 6 or 8/group) and orally administered water or S1PC (5 mg/kg, dissolved in water) once-daily for 6 weeks. Their aortas and spleens were collected after blood sampling. Macrophage polarization in the splenic lymphocytes was analyzed using flow cytometry. Protein and mRNA levels of M1/M2 macrophage markers were evaluated in the splenic lymphocytes and aortas of the mice using immunoblotting and qRT-PCR. For the experiment to examine STAT3 phosphorylation, SAMP8 mice (10 weeks old) were randomized into 5 groups (n=5/group). These mice received single oral administration of S1PC (5 mg/kg, dissolved in water) and they were sacrificed after 15–180 min. Their spleens were collected and the splenic lymphocytes were subjected to immunoblotting.

**Preparation of bone marrow-derived macrophages (BMDMs).** Bone marrow cells were collected from femurs and tibiae of C57BL/6 J mice (6–10 weeks old). Cells (5 × 10^5 cells/mL) were cultured in differentiation medium (RPMI1640 containing 10% FBS, 100 U/mL penicillin and 100 μg/mL streptomycin and 40 ng/mL M-CSF or 40 ng/mL GM-CSF) for 3 days, and then cultured for another 2 days after adding a half volume of differentiation medium. After removing non-adherent cells, adherent cells were cultured for another 2 days in the presence of 40 ng/mL M-CSF or 40 ng/mL GM-CSF.

**In vitro macrophage polarization.** For macrophage polarization analysis under non-inflammatory conditions, M-CSF-induced BMDMs were treated with 20 ng/mL mIL-10 in the presence or absence of 300 µM S1PC at 37 °C for 24 or 48 h on temperature-responsive cell culture plates (DIC). For polarization analysis under inflammatory conditions, GM-CSF-induced BMDMs were treated with 30 ng/mL mIL-10 in the presence or absence of 300 µM S1PC at 37 °C for 48 h on temperature-responsive cell culture plates, and then incubated with 100 ng/mL LPS for 16 h. The cells were plated on ice for 15 min then collected via centrifugation (1000 g, 5 min, 4 °C). The macrophage phenotypes were evaluated using flow cytometry.

**Flow cytometry.** BMDMs and splenic lymphocytes were treated with PBS containing 5% BSA and FcR blocking reagent (#130-092-575, Miltenyi Biotec) at 0–4 °C. The population of M1- (CD11b+, F4/80+, CD86+, and CD206- cells), M2- (CD11b+, F4/80-, CD86-, and CD206+ cells) and M2c-like (CD11b+, F4/80+, CD86-, CD206+, and CD150+ cells) macrophages was analyzed by a CytoFLEX using CytExpert software version 2.0.1.153 (Beckman Coulter).

**Immunoblotting.** M-CSF-induced BMDMs were cultured with mIL-10 (2 ng/mL), IL-6 (10 ng/mL), IL-4 (5 ng/mL) or IFN-γ (5 ng/mL), and LPS (25 ng/mL) in the presence of S1PC (300 µM) or AGE (2 mg/mL) at 37 °C at indicated time points. The spleens were finely crushed in HBSS containing 5% FBS using a plunger, and the red blood cells were lysed using BD Pharm Lyse buffer. The splenic lymphocytes were passed through a 40 µm cell strainer and washed with HBSS containing 5% FBS. The cells were lysed in radioimmunoprecipitation assay (RIPA) lysis buffer (Merck Millipore) containing Halt protease and phosphatase inhibitor single-use cocktail.
(Thermo Fisher Scientific). The lysates were collected by centrifugation (12,000 g, 10 min, 4 °C), and the protein levels were determined using a BCA protein assay kit (#23225, Thermo Fisher Scientific). The lysates were then boiled in sample buffer solution at 95 °C. Immunoblotting analysis was performed as previously described44,46. The blotted membranes were incubated with the indicated first antibodies and then the secondary antibodies. Immunoreactive proteins were detected using an ECL Prime western blotting detection reagent (Cytiva) or Clarity Max Western ECL substrate (Bio-Rad), and visualized bands were analyzed on a ChemiDoc Touch MP Imaging System using Image Lab software version 6.0 (Bio-Rad).

Quantitative real-time PCR (qRT-PCR). Total RNA was extracted from BMDMs, splenic lymphocytes, and aortas using RNAiso reagent (Takara Bio), and cDNA was synthesized using PrimeScript RT reagent Kit with gDNA Eraser (#RR047, Takara Bio). The quantitative real-time PCR was performed using KAPA SYBR FAST qPCR Master Mix (KAPA Biosystems) or TaqMan Fast Advanced Master Mix (#4444556, Applied Biosystems) to determine the relative expression level of target genes based on the 18S ribosomal RNA gene (Rn18s) in a CFX96 Touch Real time PCR Detection System (Bio-Rad). The primer sequences are listed in Supplemental Table S3. The relative mRNA level was calculated using the comparative CT (ΔΔCT) method.

Evaluation of STAT3 nuclear localization. M-CSF-induced BMDMs were seeded onto 8-well chamber slides and treated with mIL-10 (2 ng/mL) in the presence of S1PC (300 µM) at 37 °C for 30 or 360 min. Then, cells were fixed by 4% paraformaldehyde at 4 °C for 30 min and treated with PBS containing 5% BSA, 0.3% Triton X-100 and FcR blocking reagent at 4 °C for 15 min. Then, cells were incubated with the anti-STAT3 antibody at 4 °C for 30 min and were subsequently incubated with anti-mouse IgG-AlexaFluor 594 and Hoechst 33342 (#H3570, Thermo Fisher Scientific) at 4 °C for 30 min. Stained-cells were analyzed by a fluorescence microscope, Axio Observer7, using ZEN 3.1 pro software (ZEISS). Pearson's correlation coefficient was measured as a statistic for quantifying colocalization of STAT3 and nuclei89.

Immunoprecipitation. J774A.1 cells were maintained in RPMI1640 medium (10% FBS and 1% penicillin/ streptomycin). Cells were plated on 10 cm dishes and treated with 10 ng/mL mIL-10 in the presence of S1PC (100, 300, and 1000 µM) for 1 h and were lysed by RIPA lysis buffer containing Halt protease and phosphatase inhibitors. Anti-IL-10Rα or anti-SHIP1 antibody was incubated with Dynabeads Protein G (#DB10003, Thermo Fisher Scientific) for 10 min at RT and then cell lysates were incubated with antibody-beads complexes for 1 h at RT. Beads were washed 3 times with PBS and boiled in sample buffer solution for 10 min at 70 °C. The samples were subjected to immunoblot analysis with the indicated antibodies.

Knockdown of Inpp5d (SHIP1) gene with small interfering RNA (siRNA). J774A.1 cells seeded on 12-well plates were transfected with 2.5 pmol control siRNA (#4390843, Silencer select negative control No. 1 siRNA, Thermo Fisher Scientific) or Inpp5d (SHIP1) siRNA (#4390771, Silencer select mouse Inpp5d siRNA, ID: s68357, Thermo Fisher Scientific) using INTERFERin reagent (#409-10, Polyplus transfection) according to the manufacturer’s instructions. After 72 h of the transfection, the cells were treated with mIL-10 (10 ng/mL) for 30–180 min. The samples were subjected to immunoblot analysis with the indicated antibodies.

Cytokine measurements. For IL-10 production assay, M-CSF-induced BMDMs were cultured with 20 ng/mL hIL-10 in the presence or absence of 300 µM S1PC at 37 °C. After 48 h, cells were washed with pre-warmed PBS and then treated with 50 ng/mL LPS for 6 h. For IL-12p70 and TNF-α production assay, GM-CSF-induced BMDMs were cultured with 30 ng/mL mIL-10 in the presence or absence of 300 µM S1PC at 37 °C. After 48 h, cells were washed with pre-warmed PBS and then treated with 100 ng/mL LPS for 16 h. Culture supernatants were collected by centrifugation at 1000 g at 4 °C for 5 min. The level of each cytokine was determined by ELISA kit (#88-7105, #88-7121, and #88-7324, respectively, Thermo Fisher Scientific).

Statistical analysis. All data were subject to outliers were eliminated using Thomson’s rejection test. The statistical significance of differences was evaluated by student t-test or one-way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison test using WinSTAT statistics software version 1.2 (M. Sato, Japan). Difference at p < 0.05 was considered to be significant.
8. Ferrucci, L. & Fabbri, E. Inflammaging: chronic inflammation in ageing, cardiovascular disease, and frailty. *Nat. Rev. Cardiol.* **15**, 505–522 (2018).
9. Oishi, Y. & Manabe, I. Macrophages in age-related chronic inflammatory diseases. *NPJ Aging Mech. Dis.* **2**, 16018 (2016).
10. Di Marco, M. M-1/M-2 Macrophages and the Th1/Th2 paradigm. *J. Immunol.* **164**, 6166–6173 (2000).
11. Tökönyi, T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. *Mediators Inflamm.* **2015**, 8116460 (2015).
12. Yang, S. et al. Macrophage polarization in atherosclerosis. *Clin. Chim. Acta* **501**, 142–146 (2020).
13. Röszer, T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. *Mediators Inflamm.* **2015**, 8116460 (2015).
14. De Pauli, F., Staels, B. & Chinetti-Gbaguidi, G. Macrophage phenotypes and their modulation in atherosclerosis. *Circ. J.* **78**, 1775–1781 (2014).
15. Leitinger, N. & Schulman, I. G. Phenotypic polarization of macrophages in atherosclerosis. *Front. Immunol.* **6**, 1592–1599 (2015).
16. Nathan, C. F., Murray, H. W., Weible, I. E. & Rubin, B. Y. Identification of interferon-γ, as the lymphokine that activates human macrophages and MedTK induction. *J. Immunol.* **189**, 3508–3520 (2012).
17. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **158**, 670–689 (1997).
18. Zizzo, G., Hilliard, B. A., Monestier, M. & Cohen, P. L. Efficient clearance of early apoptotic cells by human macrophages requires SLP76 and p47phox. *Exp. Cell. Res.* **323**, 460S-463S (2016).
19. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
20. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
21. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
22. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
23. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
24. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
25. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
26. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
27. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
28. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
29. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
30. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
31. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
32. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
33. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
34. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
35. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
36. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
37. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
38. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
39. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
40. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
41. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. *J. Immunol.* **155**, 570–580 (1995).
51. Chung, S. et al. Distinct role of FoxO1 in M-CSF- and GM-CSF-differentiated macrophages contributes LPS-mediated IL-10: implication in hyperglycemia. *J. Leukoc. Biol.* 97, 327–339 (2015).

52. Karuppagounder, V. et al. Modulation of macrophage polarization and HMGB1–TLR2/TLR4 cascade plays a crucial role for cardiac remodeling in senescence-accelerated prone mice. *PLoS ONE* 11, e0152922 (2016).

53. De Paoli, F., Staels, B. & Chinneti-Gbaguidi, G. Macrophage phenotypes and their modulation in atherosclerosis. *Circ. J.* 78, 1775–1781 (2014).

54. Bi, Y. et al. M2 macrophages as a potential target for antiatherosclerosis treatment. *Neural Plast.* https://doi.org/10.1155/2019/6724903 (2019).

55. Gong, M., Zhao, X. & Ma, A. STAT6 upregulation promotes M2 macrophage polarization to suppress atherosclerosis. *Med. Sci. Monit.* Basic Res. 23, 249–257 (2017).

56. Wang, G., Liu, X., Li, X. & Zhao, Y. Suppression of PAPP-A mitigates atherosclerosis by mediating macrophage polarization via STAT3 signaling. *Biochem. Biophys. Res. Commun.* 543, 29–37 (2021).

57. Suwanpradid, J. Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. *Nat. Immunol.* 9, 1399–1406 (2008).

58. Vazquez-Dunddel, D. et al. STAT3 regulates arginase-i in myeloid-derived suppressor cells from cancer patients. *J. Clin. Invest.* 123, 1580–1589 (2013).

59. Yasukawa, H. et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. *Nat. Immunol.* 4, 551–556 (2003).

60. Seif, F. et al. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. *Cell. Commun. Signal.* 15, 23 (2017).

61. Pike, K. A. The molecular details of cytokine signaling via the JAK/STAT pathway. *Protein Sci.* 27, 193–200 (2018).

62. Perez, L. E., Desponts, C., Parquet, N. & Kerr, W. SH2-inositol phosphatase 1 negatively influences early megakaryocyte progenitors. *PLoS ONE* 3, e3565 (2008).

63. Pikes, K. A. et al. Protein tyrosine phosphatase 1B is a regulator of the interleukin-10—Induced transcriptional program in macrophages. *Sci. Signal.* 7, ra43 (2014).

64. Chamberlain, T. C. et al. Interleukin-10 and small molecule SHPII allosteric regulators trigger anti-inflammatory effects through SHIP1/STAT3 complexes. *iScience* 23, 101433 (2020).

65. Saqib, U. et al. Phytochemicals as modulators of M1–M2 macrophages in inflammation. *Oncotarget* 9, 17937–17950 (2018).

66. Liang, J. et al. Macrophage polarization in IL-10 treatment of particle-induced inflammation and osteolysis. *Am. J. Pathol.* 186, 57–66 (2016).

67. Shayganni, E., Bahmani, M., Asgary, S. & Rafieian-Kopaei, M. Inflammaging and cardiovascular disease: management by medicinal plants. *Phytomedicine* 23, 1119–1126 (2016).

68. Fassudil. The origins of age-related proinflammatory state. *Blood* 105, 2294–2299 (2005).

69. Paulusso, G. et al. Advancing age and insulin resistance: role of plasma tumor necrosis factor-a. *Am. J. Physiol. Endocrinol. Metab.* 275, E294–299 (1998).

70. Koelman, L., Pivovarova-Ramich, O., Peiffer, A. F. H., Grune, T. & Aleksandrova, K. Cytokines for evaluation of chronic inflammatory status in ageing research: reliability and phenotypic characterisation. *Immun. Ageing* 16, 11 (2019).

71. Minciullo, P. L. et al. Inflamming and anti-inflammaging: the role of cytokines in extreme longevity. *Arch. Immunol. Ther. Exp. (Warsz)* 64, 111–126 (2016).

72. Chung, H. Y. et al. Redefining chronic inflammation in aging and age-related diseases: proposal of the senoinflammation concept. *Aging Dis.* 10, 367–382 (2019).

73. Ferrucci, L. & Fabbri, E. Inflamming chronic inflammation in aging, cardiovascular disease, and frailty. *Nat. Rev. Cardiol.* 15, 505–522 (2018).

74. Teissier, T. & Boulanger, E. The receptor for advanced glycation end-products (RAGE) is an important pattern recognition receptor (PRR) for inflamming. *Biogerontology* 20, 279–301 (2019).

75. Ishida, T., Ishida, M., Tashiro, S. & Takeishi, Y. DNA damage and senescence-associated inflammation in cardiovascular disease. *Biol. Pharm. Bull.* 42, 531–537 (2019).

76. Covarrubias, A. J. et al. Senescent cells promote tissue NAD+ decline during aging via the activation of CD38+ macrophages. *Nat. Metab.* 2, 1265–1283 (2020).

77. Zheng, X. F. et al. Lipopoly saccharide-induced M2 to M1 macrophage transformation for IL-12p70 production is blocked by candida albicans mediated up-regulation of EB13 expression. *PLoS ONE* 8, e63967 (2013).

78. Zhang, Q., Lu, Y., Bian, H., Guo, L. & Zhu, H. Activation of the α7 nicotinic receptor promotes lipopolysaccharide-induced conversion of M1 microglia to M2. *Am. J. Transl. Res.* 9, 971–985 (2017).

79. Karuppagounder, V. et al. The senescence accelerated mouse prone 8 (SAMP8): a novel murine model for cardiac aging. *Ageing Res. Rev.* 35, 291–296 (2017).

80. Grifán-Ferré, C. et al. Environmental enrichment modified epigenetic mechanisms in SAMP8 mouse hippocampus by reducing oxidative stress and inflamming and achieving neuroprotection. *Front. Aging Neurosci.* 8, 241 (2016).

81. Sun, J. et al. miR-330-5p/Tim-3 axis regulates macrophage polarization and insulin resistance in diabetes mice. *Mol. Immunol.* 95, 107–113 (2018).

82. Lu, J. et al. Discrete functions of M2a and M2c macrophage subsets determine their relative efficacy in treating chronic kidney disease. *Kidney Int.* 84, 745–755 (2015).

83. Liu, C. et al. Targeting the shift from M1 to M2 macrophages in experimental autoimmune encephalomyelitis mice treated with Fasudil. *PLoS ONE* 8, 241 (2013).

84. United States Pharmacopeia 41 Garlic Fluid Extract USP28-NF33 (United States Pharmacopeial Convention, 2018).

85. Matautimo, T. & Koderz, Y. Development of an analytic method for sulfur compounds in aged garlic extract with the use of a postcolumn high performance liquid chromatography method with sulfur-specific detection. *J. Nutr.* 146, 4505–4555 (2016).

86. Amano, H., Kazamori, D. & Itoh, K. Pharmacokinetics and N-acetylation metabolism of S-methyl-l-cystine and trans-S-1-propenyl-l-cystine in rats and dogs. * Xenobiotica* 46, 1017–1025 (2016).

87. Institute of Laboratory Animal Resources (US). *Guide for the Care and Use of Laboratory Animals* 8th edn. (National Academies Press, 2011).

88. Dunn, K. W., Kamocka, M. M. & McDonald, J. H. A practical guide to evaluating colocalization in biological microscopy. *Am. J. Physiol. Cell Physiol.* 300, C723-742 (2011).

Acknowledgements

We gratefully acknowledge Dr. Chiemi Sakai, Dr. Hiromitsu Watanabe, and lab members at Department of Cardiovascular Physiology and Medicine, Hiroshima University for many helpful discussions. We thank Dr. Takami Oka at Wakunaga Pharmaceutical Co. Ltd. for many helpful discussions and useful advices.
Author contributions
S.M., J.S., M.I., H.K., and M.Y. conceived and designed study. S.M. and J.S. performed the experiments and analyzed data. S.M., J.S., M.T., M.I., H.K., and M.Y. drafted and revised the paper. All authors approved the final version of the manuscript.

Competing interests
Some of the authors (S.M., J.S., and M.T.) are employed by Wakunaga Pharmaceutical Co., Ltd. and are listed in the affiliation section. The employment does not affect each researcher's conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript. This study revealed the new biological activity of AGE and S1PC in the experiment systems. The company has no financial interest in this publication. All other authors have no conflict.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-01866-3.

Correspondence and requests for materials should be addressed to S.M. or M.Y.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021